October 17, 2026 05:58 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
'How dare Elon Musk?' Owaisi defends Modi after billionaire's 'real boss' jibe at Ambani | 'B****y S***': IAS officer's abuse of female colleague during virtual J&K meeting sparks row | Aamir Khan’s nephew Imran Khan asked to leave India by Oct 28 after joining anti-CEC protest | ‘Their crime? Demanding justice’: Rahul Gandhi slams 4 AM detention of Ankita Bhandari’s parents | ‘Bangladesh showed us the way’: Neha Bora’s remarks spark BJP attack on Rahul Gandhi | Chingrighata flyover skid scare: Bikes fall, anti-skid blocks installed overnight as Bengal Minister Agnimitra Paul faces criticism | Meerut blue drum murder case: Muskaan, her lover get death sentence | 'Rise up, young patriots!': American singer Mary Millben alleges CJP gets US funding, urges peaceful protests | 'Won't go unchallenged': Muhammad Yunus heckling in New York triggers legal action warning | flydubai cockpit attack probe widens: Two Maldivian pilots detained in UAE over links to Omani co-pilot

Aurobindo Pharma receives USFDA approval for drug related to moderate dementia

| | Mar 29, 2016, at 08:16 pm
Hyderabad/Mumbai, Mar 29 (IBNS) Aurobindo Pharma Limited, which manufactures generic pharmaceuticals and active pharmaceutical ingredients, announced on Tuesday that the company has received the final approval from the US Food & Drug Administration (USFDA) to manufacture and market Rivastigmine Tartrate Capsules USP, 1.5 mg, 3 mg, 4.5 mg and 6 mg.
This product is expected to be launched in the first quarter of fiscal year 2016-17.
 
The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Exelon Capsules, 1.5 mg, 3 mg, 4.5 mg and 6 mg, of Novartis Pharmaceuticals Corporation, said the company.
 
Naproxen Sodium Tablets is used in the treatment of mild moderate dementia of the Alzheimer's and Parkinson's disease. 
 
The approved product has an estimated market size of US$ 26.7 million for the twelve months ending January 2016 according to IMS.
 
This is the 67th ANDA (including 14 tentative approvals) to be approved out of Unit VII formulation facility in Hyderabad, India for manufacturing oral non-antibiotic products. 
 
Aurobindo now has a total of 246 ANDA approvals (211 Final approvals including 10 from Aurolife Pharma LLC and 35 tentative approvals) from USFDA.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.